RxDoctor Payments Data

Charles Gornick, MD

Clinical Cardiac Electrophysiology · Minneapolis, MNNPI 1376597237

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Biosense Webster, Inc. accounts for 68.8% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in MN, where the typical reported total is $10,629.

$43in general payments, 2019–2025

Across 2 payments — averaging $21.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biosense Webster, Inc.$29
  • Pfizer$13
$106,726in research payments, 2019–2025

Across 37 payments — averaging $2884.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$81K
  • Boston Scientific$26K

What the payments were for

  • Food & beverage$43100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biosense Webster, Inc.1$29
Pfizer1$13

How this compares

$43 in reported general payments places this provider in the 10th percentile of 72 clinical cardiac electrophysiology providers in Minnesota.

See all clinical cardiac electrophysiology providers in Minnesota

Medicare billing

Part B allowed, 2024
$163,978
Medicare patients
1,073
Services billed
2,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban194$239,683
XareltoRivaroxaban47$69,194
EntrestoSacubitril/Valsartan31$27,075
Flecainide Acetate85$5,410
SotalolSotalol Hcl154$4,337
Metoprolol Succinate110$2,443
Propafenone Hcl46$2,320
Losartan Potassium79$1,509
Clonidine19$1,357
Amiodarone Hcl63$1,342
Lisinopril88$1,300
Metoprolol Tartrate88$1,050
Digoxin35$961
Amlodipine Besylate63$887
Carvedilol77$849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$239,683194 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 72 clinical cardiac electrophysiology providers in Minnesota.

Other clinical cardiac electrophysiology in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →